Get the Stockscreener App
7.55
0.80%
0.06
Gyre Therapeutics Inc stock is traded at $7.55, with a volume of 47,506.
It is up +0.80% in the last 24 hours and down -9.47% over the past month.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
See More
Previous Close:
$7.49
Open:
$7.42
24h Volume:
47,506
Relative Volume:
0.56
Market Cap:
$727.32M
Revenue:
$106.66M
Net Income/Loss:
$15.16M
P/E Ratio:
80.75
EPS:
0.0935
Net Cash Flow:
$6.37M
1W Performance:
-5.51%
1M Performance:
-9.47%
6M Performance:
-27.19%
1Y Performance:
-35.74%
1-Day Range:
$7.39
$7.66
1-Week Range:
$7.39
$8.47
52-Week Range:
$6.11
$14.42
Gyre Therapeutics Inc Stock (GYRE) Company Profile
Name
Gyre Therapeutics Inc
Sector
Industry
Phone
(858) 567-7770
Address
12770 HIGH BLUFF DRIVE, SAN DIEGO
Compare GYRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GYRE
Gyre Therapeutics Inc
|
7.55 | 721.54M | 106.66M | 15.16M | 6.37M | 0.0935 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gyre Therapeutics Inc Stock (GYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | Jefferies | Buy |
| Aug-26-25 | Initiated | H.C. Wainwright | Buy |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
View All
Gyre Therapeutics Inc Stock (GYRE) Latest News
Is Gyre Therapeutics Inc. stock a dividend growth opportunity2025 Short Interest & Real-Time Volume Triggers - newser.com
Is Gyre Therapeutics Inc. stock dividend yield sustainableJuly 2025 Closing Moves & Safe Entry Point Identification - newser.com
What drives Gyre Therapeutics Inc stock priceMarket Capitalization Trends & Free Triple Digit Wealth Increase - earlytimes.in
Will Gyre Therapeutics Inc. stock return to pre crisis levelsLong Setup & Low Risk High Win Rate Picks - newser.com
Should I hold or sell Gyre Therapeutics Inc. stock in 2025July 2025 Final Week & Verified Technical Signals - newser.com
Why Gyre Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Weekly Chart Analysis and Guides - newser.com
What recovery options are there for Gyre Therapeutics Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Can Gyre Therapeutics Inc. stock sustain institutional interest2025 Biggest Moves & Smart Money Movement Tracker - newser.com
How Gyre Therapeutics Inc. stock performs in interest rate cyclesMarket Activity Recap & Daily Volume Surge Signals - newser.com
Is Gyre Therapeutics Inc. stock entering bullish territoryTrade Entry Summary & Long-Term Safe Investment Ideas - newser.com
Gyre Therapeutics, Inc. (NASDAQ:GYRE) Receives $17.00 Average PT from Brokerages - Defense World
Will breakout in Gyre Therapeutics Inc. lead to full recoveryMarket Growth Report & Low Drawdown Momentum Trade Ideas - newser.com
How to forecast Gyre Therapeutics Inc. trends using time series2025 Volatility Report & Safe Entry Momentum Tips - newser.com
Analyzing Gyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Reliable Breakout Stock Forecasts - newser.com
Published on: 2025-11-16 00:46:46 - newser.com
Trend analysis for Gyre Therapeutics Inc. this weekQuarterly Trade Review & Risk Adjusted Buy/Sell Alerts - newser.com
What institutional flow reveals about Gyre Therapeutics Inc.Entry Point & Step-by-Step Swing Trade Plans - newser.com
Gyre Therapeutics (NASDAQ:GYRE) Stock Rating Upgraded by Wall Street Zen - Defense World
Is this a good reentry point in Gyre Therapeutics Inc.2025 Key Lessons & Long-Term Capital Growth Strategies - newser.com
Statistical indicators supporting Gyre Therapeutics Inc.’s strength2025 Market Overview & Smart Investment Allocation Insights - newser.com
Exploring High Growth Tech Stocks in the US Market - simplywall.st
Gyre Therapeutics' (NASDAQ:GYRE) Promising Earnings May Rest On Soft Foundations - 富途牛牛
We Think That There Are Issues Underlying Gyre Therapeutics' (NASDAQ:GYRE) Earnings - Yahoo Finance
Q1 EPS Estimate for Gyre Therapeutics Decreased by Analyst - Defense World
COO Ye Files To Sell 548,000 Of Gyre Therapeutics Inc [GYRE] - TradingView
Gyre Therapeutics Inc Stock (GYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):